Currently Viewing:
Cost-Sharing Roundtable — The Patient Assistance Safety Net: How Many Need Help? How Many Are Helped?
Michele McCourt Explains CancerCare's Role in Supporting Patients
May 20, 2018
Kristina Wharton: More Funding Needed to Support FQHCs
May 13, 2018
Paul Billings Discusses the Financial Burden of Prescription Drug Costs in Medicare
May 10, 2018
Michele McCourt Outlines Financial Burdens Related to Cancer Treatment
May 08, 2018
Dan Klein on the Growing Role of Charitable Organizations Like PAN Foundation
May 02, 2018
Michele McCourt on Directing Patients to Financial Medication Assistance
April 28, 2018
Kristina Wharton on the Increased Use of Services Provided by FQHCs
April 25, 2018
Dan Klein Explains the Need for Patient Assistance Foundations
April 22, 2018
Currently Reading
Leigh Purvis Outlines the Burdens of High Drug Costs on Medicare Beneficiaries
April 20, 2018
Ed Haislmaier on Efforts to Lower Drug Costs
April 15, 2018
Dr Todd Yezefski on the Benefits of Financial Navigators in Oncology
April 14, 2018
Kristina Wharton Discusses Services Provided at Federally Qualified Health Centers
April 09, 2018
Dan Klein Outlines Policy Changes to Strengthen the Safety Net
April 05, 2018
Ed Haislmaier: Medicare Is "Stuck in a Time Warp"
April 04, 2018
Leigh Purvis on Out-of-Pocket Costs for Medicare Beneficiaries
March 31, 2018
Dr Todd Yezefski Discusses the Financial Hardships of Cancer Treatment
March 30, 2018
Kristina Wharton Analyzes the Health of the Population Using FQHCs
March 29, 2018
Michele McCourt Discusses Impact of High Costs for Patients With Cancer
March 27, 2018
Dan Klein on Lack of Cost Sharing in Medicare, Drugs Coming Down the Pipeline
March 27, 2018

Leigh Purvis Outlines the Burdens of High Drug Costs on Medicare Beneficiaries

Leigh Purvis, director of Health Services Research at AARP Public Policy Institute, addresses the burdens of high prescription drug costs on Medicare beneficiaries.


Leigh Purvis, director of Health Services Research at AARP Public Policy Institute, addresses the burdens of high prescription drug costs on Medicare beneficiaries.

Transcript

How does the burden of high prescription drug costs among the Medicare population differ from the general population?

I think the biggest difference that we’re seeing in terms of high cost drugs for Medicare beneficiaries is that under Medicare Part D there is a lot of coinsurance which is where they are responsible for a percentage of the drug cost as opposed to a flat copayment, and that type of payment structure hasn’t stretched too other forms of insurance yet. So, we are seeing Part D beneficiaries being responsible for much more of the cost than we see in other forms of insurance.

How do Medicare beneficiaries usually handle being faced with the donut hole after coming employer-sponsored insurance, where they didn’t have to deal with it?

Unfortunately, we see a lot of people either walking away from the pharmacy counter or trying to find other ways of getting their prescription drugs which is a problem because they are obviously operating outside of the system or they’re not treating the conditions that need to be treated, and that can ultimately lead to higher health care costs down the road.

What impact do you see new treatments that are very effective, but very expensive, having on Medicare and patients?

I think both of them are being negatively affected. Innovation is great, but it’s only great if you can afford to use it and, unfortunately, that’s kind of the trade-off that we are facing right now and we want to make sure that we are having access to these innovative therapies. The Medicare program is a tax-payer funded program and the more it’s spending on these types of products, the more tax payers are spending on these types of products, the more beneficiaries that are being asked to spend on these types of products. Unfortunately, I think about these groups, MedPack included, that have come to the conclusion that it’s really unsustainable. It pushes us to a precipice where people can’t access the drugs that they need.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!